October 21, 2010
Herceptin approved for HER2-positive metastatic stomach cancer
Herceptin is already indicated for the treatment of HER2-expressing metastatic breast cancer as a single agent in patients who have received one or more chemotherapy regimens; or in combination with paclitaxel in patients who have not received chemotherapy. Herceptin is also indicated as adjuvant treatment in HER2-expressing, node-positive or node-negative breast cancer (as a single agent following multi-modality anthracycline based therapy; in combination with doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; or in combination with docetaxel and carboplatin).
For more information call (650) 225-1000 or visit www.herceptin.com.